1986
A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate.
Seifter E, Bunn P, Cohen M, Makuch R, Dunnick N, Javadpour N, Bensimon H, Eddy J, Minna J, Ihde D. A trial of combination chemotherapy followed by hormonal therapy for previously untreated metastatic carcinoma of the prostate. Journal Of Clinical Oncology 1986, 4: 1365-73. PMID: 2943877, DOI: 10.1200/jco.1986.4.9.1365.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCisplatinClinical Trials as TopicCyclophosphamideDiethylstilbestrolDoxorubicinDrug Therapy, CombinationHumansMaleMedroxyprogesteroneMedroxyprogesterone AcetateMiddle AgedNeoplasm MetastasisOrchiectomyPilot ProjectsProstatic NeoplasmsConceptsHormonal therapyCombination chemotherapyStable diseasePartial responseHormonal manipulationResponse rateInitial hormonal therapySubsequent hormonal manipulationUntreated metastatic carcinomaObjective response rateIntensive combination chemotherapyNormal testosterone levelsMetastatic prostate cancerEfficacy of chemotherapyProgression of diseaseTime of deathSimilar chemotherapyEndocrine treatmentUntreated patientsObjective responseOverall survivalMetastatic carcinomaModest efficacySerum testosteroneProstate cancerPulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer.
Brooks B, Seifter E, Walsh T, Lichter A, Bunn P, Zabell A, Johnston-Early A, Edison M, Makuch R, Cohen M. Pulmonary toxicity with combined modality therapy for limited stage small-cell lung cancer. Journal Of Clinical Oncology 1986, 4: 200-9. PMID: 3003259, DOI: 10.1200/jco.1986.4.2.200.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Small CellCombined Modality TherapyCyclophosphamideDoxorubicinFemaleHumansLomustineLung NeoplasmsMaleMethotrexateMiddle AgedProcarbazinePrognosisProspective StudiesPulmonary FibrosisRadiographyRandom AllocationRespiratory Function TestsVincristineConceptsPulmonary function testsLimited stage small cell lung cancerStage small cell lung cancerSmall cell lung cancerModality therapyPulmonary toxicityPulmonary complicationsVital capacityLung cancerRadiation therapyLife-threatening pulmonary toxicityInitial pulmonary function testLower vital capacitySubsequent pulmonary complicationsBilateral pulmonary infiltratesDisease-free survivalModality armPulmonary infiltratesPulmonary morbidityExpiratory volumeOverall survivalPerformance statusProspective trialClinical courseHospital admission
1983
Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response
Rosen S, Makuch R, Lichter A, Ihde D, Matthews M, Minna J, Glatstein E, Bunn P. Role of prophylactic cranial irradiation in prevention of central nervous system metastases in small cell lung cancer Potential benefit restricted to patients with complete response. The American Journal Of Medicine 1983, 74: 615-624. PMID: 6301274, DOI: 10.1016/0002-9343(83)91019-7.Peer-Reviewed Original ResearchConceptsCentral nervous system metastasesProphylactic cranial irradiationNervous system metastasesCranial irradiationComplete responsePrognostic featuresSystemic therapyCentral nervous system relapseSmall cell lung cancerInvolvement of liverPercent of patientsNervous system relapseSystemic combination chemotherapySubset of patientsTwo-year survivalCell lung cancerStage of diseaseCentral nervous systemNational Cancer InstituteChest irradiationComplete remissionEpidural metastasesOverall survivalCombination chemotherapyIntracerebral metastases
1981
Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial
Fisher R, Terry W, Hodes R, Rosenberg S, Makuch R, Gordon H, Fisher S. Adjuvant Immunotherapy or Chemotherapy for Malignant Melanoma: Preliminary Report of the National Cancer Institute Randomized Clinical Trial. Surgical Clinics Of North America 1981, 61: 1267-1277. PMID: 7031934, DOI: 10.1016/s0039-6109(16)42582-x.Peer-Reviewed Original ResearchConceptsBacille Calmette-GuerinDisease-free intervalAdjuvant immunotherapyClinical trialsMalignant melanomaStage I malignant melanomaStage II melanomaSurvival of patientsNational Cancer InstituteOverall survivalPostsurgical patientsMethyl-CCNUCalmette-GuerinCancer InstituteMelanoma cellsMelanomaFurther treatmentPreliminary reportImmunotherapyChemotherapyPatientsTrialsSurvivalSignificant improvement